NCT00256542已完成2 期
A Phase II Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intravesical Alkalinized Lidocaine-Heparin for the Symptoms of Pelvic Pain and/or Urgency of Bladder Origin
Urigen18 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2006年1月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 90
- 试验地点
- 18
- 主要终点
- Overall improvement in combined symptoms of pain and urgency at 3 weeks
研究概览
简要总结
The purpose of this study is to determine whether intravesical U101 (alkalinized lidocaine-heparin) treatment reduces the symptoms of pelvic pain and/or urgency of bladder origin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects at least 18 years of age.
- •Subjects must have given written informed consent to participate in this trial.
- •All female subjects, except those who are post-menopausal and/or surgically sterilized, must consent to use two medically acceptable methods of contraception throughout the entire study period. Medically acceptable methods of contraception that may be used by the subject and/or her partner include: abstinence, birth control pills, diaphragm with spermicide, intrauterine device (IUD), condom and foam, vaginal spermicidal suppository, progestin implant, and Depo-Provera injections.
- •Subjects must have had symptoms of pelvic pain and/or urgency.
- •Medical history and physical examination results must be clinically acceptable to the Investigator. Medical Monitor may evaluate subjects who don't meet eligibility criteria.
- •Female subjects currently using hormone therapy (HT) must have been using HT for at least 3 months.
排除标准
- •Subjects less than 18 years of age.
- •Subjects with known hypersensitivity to heparin or lidocaine.
- •Female subjects who have a positive pregnancy test at the time of screening, who are pregnant or lactating, or who are planning to become pregnant during the study period.
- •Subjects who are chronic users of narcotics or who are using any narcotics at the time of study entry.
- •Subjects who have hepatic disease or clinically significant abnormal liver function tests (more than twice the upper limit of the normal range).
- •Subjects who do not expect to be available for the entire duration of the study.
- •Subjects with any coexisting significant medical condition that is likely to interfere with study procedures (cardiovascular, hematological, central nervous system, pulmonary, renal, etc.)
- •Subjects who have been treated with dimethyl sulfoxide (DMSO) or other bladder instillation therapies within three months prior to study entry.
- •Subjects who have had cystoscopic dilatation of their bladder or urethra within three months of study entry.
- •Subjects who have taken or used any investigational drug or device within 30 days before the start of the study, or who are currently enrolled in another investigational study.
- •Subjects contemplating having or scheduled for any invasive surgical procedures during the study period.
- •Subjects who are unwilling or unable to abide by the requirements of the study.
- •History of gastrointestinal (GI) bleeding
- •Active bleeding from any source
- •Screening activated partial thromboplastin time (aPTT) above normal limits
- •Systolic blood pressure (BP) > 180 mmHg or < 90 mmHg at Screening.
- •Subjects with an actively bleeding lesion/area in the bladder as detected by urinalysis
结局指标
主要结局
Overall improvement in combined symptoms of pain and urgency at 3 weeks
次要结局
- Safety
- Reduction in pain on ten point scale at 3 weeks
- Reduction in urgency on ten point scale at 3 weeks
- Change in number of voids/24 hours
- Change in average void volume
- Reduction in PUF score (pelvic pain, urgency/frequency) at 3 weeks
- Reduction in O'Leary-Sant score at 3 weeks
研究者
研究点 (18)
Loading locations...
相似试验
招募中
1 期
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2High-risk Non-muscle Invasive Bladder CancerNCT06378242RemeGen Co., Ltd.24
招募中
1 期
Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder CancerNon Muscle InvasiveBladder CancerNCT06732531Zhuhai Beihai Biotech Co., Ltd48
已完成
1 期
VPM1002BC in Recurrent Non-muscle Invasive Bladder CancerBladder CancerNCT02371447Swiss Group for Clinical Cancer Research39
已完成
1 期
Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder CancerNon-muscle Invasive Bladder CancerNCT01458847BioCis Pharma Ltd12
已完成
不适用
Phase I/IIa study of intravesical administration of 2-methyl-3-butenyl-1-pyrophosphate-stimulated gamma delta T cells in patients with non-invasive bladder cancer.on-invasive bladder cancerJPRN-UMIN000010942Tokyo Women's Medical University12